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The Prospective Dutch Colorectal 
Cancer (PLCRC) cohort: real‑world 
data facilitating research 
and clinical care
Jeroen W. G. Derksen1,2, Geraldine R. Vink1,3, Marloes A. G. Elferink3, 
Jeanine M. L. Roodhart1, Helena M. Verkooijen4, Wilhelmina M. U. van Grevenstein5, 
Peter D. Siersema6,7, Anne M. May2,63, Miriam Koopman1,63* & The PLCRC Study Group*
Real‑world data (RWD) sources are important to advance clinical oncology research and evaluate 
treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, 
linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research 
collecting additional patient‑reported outcomes (PRO) and biospecimens. Here we report on 
cohort developments and investigate to what extent PLCRC reflects the “real‑world”. Clinical and 
demographic characteristics of PLCRC participants were compared with the general Dutch CRC 
population (n = 74,692, Dutch‑ref). To study representativeness, standardized differences between 
PLCRC and Dutch‑ref were calculated, and logistic regression models were evaluated on their ability 
to distinguish cohort participants from the Dutch‑ref (AU‑ROC 0.5 = preferred, implying participation 
independent of patient characteristics). Stratified analyses by stage and time‑period (2013–2016 
and 2017–Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 
patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 
2136 (50 of 75 Dutch hospitals) in 2018. Low AU‑ROC (0.65, 95% CI: 0.64–0.65) indicates limited ability 
to distinguish cohort participants from the Dutch‑ref. Characteristics that remained imbalanced in 
the period 2017–Aug’19 compared with the Dutch‑ref were age (65.0 years in PLCRC, 69.3 in the 
Dutch‑ref) and tumor stage (40% stage‑III in PLCRC, 30% in the Dutch‑ref). PLCRC approaches to 
represent the Dutch CRC population and will ultimately meet the current demand for high‑quality 
RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC’s 
representativeness and its contribution to a learning healthcare system.
Global colorectal cancer (CRC) incidence is expected to increase in the coming  decades1, which emphasizes the 
need to fulfill current knowledge gaps and improve clinical outcomes. In the current era of precision medicine, 
smaller treatment‐eligible target populations are both an advancement as well as a challenge in cancer  research2,3. 
Due to the large amount of CRC subgroups defined by clinical characteristics in combination with the many 
(low-frequency) molecular  markers4–6, the enrollment of sufficiently large sample sizes in studies evaluating 
the safety and efficacy of new therapeutic agents is a growing challenge. In addition, selective enrollment in 
most phase III randomized clinical trials (RCTs) may affect the generalizability of trial results and limits our 
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understanding of the “true” treatment’s benefit-risk profile in the broader patient population. This is a constraint 
in clinical cancer research, given that international clinical guidelines are often based on results from strongly 
selected trial populations.
As advocated by both the research community and regulators such as the U.S. Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA), the development of high quality population-based studies 
in cancer patients that provide real-world data (RWD) is a major research priority to overcome challenges in 
research methodologies, complement RCT data, and ultimately improve patient  outcomes7,8. A learning health-
care system approach, defined as a circular system in which “science, informatics, incentives, and culture are 
aligned for continuous improvement and innovation, with best practices seamlessly embedded in the delivery 
process and new knowledge captured as an integral by-product of the delivery experience”9, uses RWD to accel-
erate knowledge generation and its translation into clinical practice. RWD mainly distinguishes itself from trial-
based evidence by being population-level data originating from sources outside of the typical clinical research 
setting, such as electronic health records (EHRs) or cancer registries, with the potential to efficiently answer 
research questions relevant to the broader patient  population10. To warrant high quality RWD, ascertaining a 
high quality of primary data (i.e. completeness and accuracy of EHRs), linkage of data sources, and quality of 
derived variables, is  paramount11,12. Altogether, a prospective “real-world” cohort requires longitudinal patient, 
treatment (sequences), and outcome data from an unselected and representative patient population.
Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort collects extensive longitudinal clinical 
data, together with blood, (tumor) tissue, and repeated patient-reported outcomes (PROs) in patients with stage 
I to IV CRC that are prospectively followed from primary diagnosis until  death13. PLCRC serves as an infrastruc-
ture for a wide variety of research projects including etiological, biomarker, basic, (epi)genetic, and interventional 
[according to the Trials within Cohorts (TwiCs)  design14], as well as health-care policy and cost-effectiveness 
studies. In order for results to be generalizable, and for accurate evaluation of cancer treatments, it is important 
to obtain a cohort that consists of a demographically and clinically representative patient population. Therefore, 
the aims of this manuscript are to (1) describe developments towards a nationwide cohort, (2) provide baseline 
characteristics, including PROs, of the first 5722 participants, and (3) investigate to what extent PLCRC reflects 
the “real-world”—over time and by tumor stage—by comparing PLCRC cohort participants with the general 
Dutch CRC population as registered in the Netherlands Cancer Registry (NCR).
Methods
PLCRC is an initiative coordinated by the Dutch Colorectal Cancer Group (DCCG) and is registered at Clini-
caltrials.gov (NCT02070146). The ‘Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE)’ guidelines were taken into account when the cohort was  designed15. We here describe the cohort 
briefly since the detailed design is published  elsewhere13.
The PLCRC population. PLCRC consists of patients diagnosed with a malignancy of the colon and/or 
rectum (ICD-10, C18-20) in the Netherlands. Each patient with histologically proven, or a strong suspicion of 
CRC without pathological confirmation, who is ≥ 18 years of age is eligible. The informed consent procedure is 
preferably performed shortly after diagnosis and before treatment starts. However, patients can also be enrolled 
during treatment or follow-up. Consent for longitudinal clinical data collection is mandatory for participation. 
In addition, patients can choose to consent to other optional items as shown in Box 1. Patients enrolled before 
August 1, 2019 of whom complete clinical data of the initial diagnosis and treatment period were available—to 
ascertain correct classification of tumor stage—were included in the analyses. Of these patients, baseline demo-
graphic and clinical data were retrieved and reported, as well as self-reported physical activity, fatigue, quality 
of life, BMI, presence of chronic comorbidities, smoking behavior, alcohol consumption, education level, and 
living situation at baseline.
The Netherlands Cancer Registry (NCR). The Netherlands Cancer Registry (NCR) contains an exten-
sive set of clinical data—from diagnosis onwards—of individuals diagnosed with cancer in the Netherlands and 
has a national coverage of over 95%16. Clinical data of the complete treatment trajectory are retrieved from EHRs 
and entered into the NCR. Importantly, the completeness of the NCR therefore depends on the completeness 
of EHRs. Overall, the NCR’s high quality is assured by thorough training of data managers and computerized 
consistency checks. PLCRC’s informed consent allows for linkage with the NCR and thus ensures the availability 
of clinical data over the complete cancer trajectory.
For the current analysis, only data of the initial data registration phase, i.e. at diagnosis, were used. We com-
pared characteristics of PLCRC participants with the general Dutch CRC population (Dutch-ref) from the NCR 
with incidences between January 1, 2013 and December 31, 2017.
Statistical analysis. Descriptive statistics were used to describe baseline patient characteristics, including 
baseline PROs. Standardized differences (d) were calculated to quantify the magnitude of differences in patient 
characteristics between PLCRC participants and the Dutch-ref. Values greater than 0.20 indicate a large imbal-
ance, while values between 0.10 and 0.20 indicate a small imbalance, and standardized differences less than 0.10 
indicate a negligible  imbalance17,18. Results are shown for the total group and stratified by tumor stage and time 
of enrollment. Two time-periods (enrolled between 2013–‘16 and 2017–August ’19) were evaluated to assess 
whether PLCRC participants became more representative of the Dutch-ref over time. Logistic regression models 
were used to investigate to what extent, based on the available a priori selected patient characteristics (i.e. age, 
sex, primary tumor location and tumor stage), cohort participation could be  predicted19. Model performance 
was assessed based on calibration and  discrimination20. Calibration—the goodness of fit—was evaluated using 
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the Hosmer–Lemeshow  test21. Discrimination refers to the ability to distinguish cohort participants from non-
participants, and was quantified by the area under the receiver operating characteristic curve (AU-ROC)20. The 
AU-ROC ranges from 1, corresponding to perfect discrimination, to 0.5, corresponding to a model with no 
discrimination ability, here preferred and defined as cohort participation independent of patient characteris-
tics (0.5 = random chance, 0.5–0.7 = poor, 0.7–0.8 = good, 0.8–1.0 = strong, 1.0 = perfect prediction)22. Statistical 
analyses were performed using STATA (Release 15, Stata Corp LLC, College Station, TX) and SPSS (version 25.0, 
IBM Corp, Armonk, NY).
Ethics approval. The study protocol was approved by the Institutional Review Board of the University 
Medical Center Utrecht (The Netherlands). All procedures performed that involved human participants were 
in accordance with the institutional and/or national ethical standards and guidelines as well as with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards.
Consent to participate. Informed consent was obtained from all individual participants included in the 
study.
Results
The flowchart for the selection of individuals for the current analyses is shown in Fig. 1. On August 1, 2019, a 
total of 5744 patients were enrolled. A complete TNM tumor stage could not be retrieved for 22 patients, who 
were therefore not included in the analyses.
Developments towards a nationwide cohort. PLCRC has continuously strengthened its infrastruc-
ture to improve the enrollment rate. In August 2019, patients were enrolled in 50 of 75 Dutch hospitals including 
7 (of 8) academic hospitals, 22 (of 26) top clinical hospitals that focus on education and research, and 21 (of 41) 
regular hospitals (Fig. 2). This led to an improved annual enrollment-rate, from 129 participants from 1 recruit-
ing hospital in 2013 to 2136 from 50 recruiting hospitals in 2018 (note that there are approx. 14,000 incident 
cases annually). At enrollment, 100% of patients consented for using their clinical data obtained from the NCR, 
which was mandatory, 81% consented to receive repeated PRO questionnaires, 83% for blood withdrawals, 95% 
for use of tissue for scientific research, 83% for contact when relevant DNA abnormalities are found, and 78% 
for future research and trials according to the TwiCs design (Fig. 3). Once consented to receive questionnaires 
for PROs, 77% of patients returned their baseline questionnaire, and completion rates remained above 60% in 
the first three years after enrollment (Fig. 4). Interestingly, patients who received paper-based questionnaires had 
consistently higher completion rates compared to electronic questionnaires (85% vs. 72% at baseline, respectiv
ely).
Baseline patient characteristics. The cohort contained 851 patients with stage I CRC, 1079 with stage 
II, 1960 with stage III, 946 with stage IV, and 886 patients of whom data on tumor stage is still being collected 
(Table 1). The median number of days from diagnosis until enrollment was 18 (IQR: 1 to 131) for the total 
cohort, and was similar for all stages except for stage IV patients, who were enrolled much later in the cancer 
Box 1.  Informed consent options and main objectives of PLCRC.
IC options within the PLCRC cohort
Mandatory
1. Informed consent for longitudinal observational clinical data collection
Optional
2. Informed consent for providing PRO (hard-copy or electronic)
 (a) In case of electronic patient-reported outcomes (ePRO), patients can choose to receive a summarized evaluation of their HRQoL (incl. 
optional comparisons with average scores of sex- and age-matched CRC patients and/or the non-cancer population) and share these data 
with their healthcare professional
3. Informed consent to approach the patient for future studies and to use their data in comparative research according to the Trials within 
Cohorts (TwiCs) design
4. Informed consent for biobanking of (tumor) tissue
5. Informed consent for providing additional blood samples during routine blood withdrawal for observational studies or biobanking
6. Informed consent to receive information in case of new relevant DNA abnormalities
Objectives of the PLCRC cohort
To prospectively collect detailed data on medical history, serious comorbidities, basic physical examination, imaging results, pathology 
results, tumor characteristics, treatments, treatment outcomes, hospital stays, interventions and adverse events
To collect blood and (tumor) tissue material, obtained during routine practice, for ongoing and future research
To provide more accurate treatment data, and clinical and patient-reported outcomes of CRC in daily clinical practice
To create a continuous basis for a large variety of research purposes including, but not limited to:
 Etiologic, diagnostic, and prognostic research
 Basic and (epi)genetic research
 Interventional studies according to TwiCs designs
 Healthcare policy and cost-effectiveness studies
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PLCRC cohort
Table 2 and 3
Table 1
Total cohort on August 1st 2019 
n=5,744
Unable to retrieve a 
complete TNM a
n=22
Cohort without unknown TNM 
n=5,722





PLCRC patient selection 
Figure 1.  Flow diagram of the selection of individuals for the current analyses. aInsufficient data in patient’s 
EHRs for the NCR to collect a complete TNM stage. bMissing due to time-lag in NCR clinical data collection. 
This number is higher than presented in Table 1, as for some cases sufficient staging information was available to 
classify into TNM stage.
Figure 2.  PLCRC recruiting hospitals (academic, non-academic, and top clinical hospitals) over time. Note: In 
The Netherlands there is a total of 75 hospitals, of which 8 academic hospitals and 26 top-clinical hospitals.
Figure 3.  Baseline informed consent percentages per item. The use of clinical NCR data is 100% since this item 
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trajectory (188 [IQR: 23 to 670] days). The percentage of males was higher than females for all stages, and 61% 
of the patients had a primary tumor located in the colon, and 39% in the rectum. Of the 946 stage IV patients, 
79% had synchronous liver, 22% lung, and 17% peritoneal metastases. Regarding molecular diagnostics at diag-
nosis, RAS status was available in 596 (10%) patients, BRAF in 570 (10%), and microsatellite instability (MSI) in 
2600 (45%). In terms of physical and psychological wellbeing at enrollment (supplementary Table 1), patients 
reported to experience impaired psychosocial functioning, and high levels of fatigue, appetite loss and diarrhea 
as compared to reference populations (refs).
PLCRC versus the general Dutch CRC population. While the logistic regression model including age, 
sex, primary tumor location, and tumor stage overestimates the probability of participation (p < 0.001), the low 
discriminative power (AU-ROC 0.65, 95% CI: 0.64–0.65) indicates limited ability to distinguish cohort partici-
pants from the Dutch-ref, based on available data (full ROC curves in supplementary Fig. 1). This discrimination 
decreased over time from an AU-ROC of 0.70 (95% CI: 0.68–0.71) in PLCRC’s initial phase (2013–‘16) to 0.64 
(95% CI: 0.63–0.64) in the most recent phase (2017–Aug ‘19).
Between PLCRC participants (n = 4759) and the Dutch-ref (n = 72,685), large imbalances were found for 
age at diagnosis (64.9 years in PLCRC, 69.3 in the Dutch-ref,  dage 0.41), primary tumor location (43% rectum 
in PLCRC and 31% in the Dutch-ref,  dpr.tumor 0.24) and TNM stage (41% stage III in PLCRC and 30% in the 
Dutch-ref,  dtnm 0.24), a small imbalance in sex (62% male in PLCRC and 57% in the Dutch-ref,  dsex 0.11), and 
negligible imbalances in BMI at diagnosis (26.6 in PLCRC and 26.6 in the Dutch-ref,  dbmi 0.01) and in location 
of synchronous metastasis (15% liver in PLCRC and 15% in the Dutch-ref,  dmeta between 0.01 and 0.08), Table 2.
When the two time-periods were compared with the Dutch-ref to study PLCRC’s evolution, a large imbalance 
remained for age at diagnosis and tumor stage  (dage from 0.45 to 0.40,  dtnm from 0.33 to 0.22). The distribution 
of sex, BMI at diagnosis, and primary tumor location improved to imbalances classified as small or negligible 
 (dsex from 0.17 to 0.09,  dbmi from 0.16 to 0.03,  dpr.tumor from 0.53 to 0.16). For location of synchronous metastases, 
e.g. liver metastasis, the imbalance compared with the Dutch-ref was negligible in both time periods  (dliver from 
0.08 to 0.04).
Table 3 shows stratified analyses in which PLCRC participants were compared with the Dutch-ref by tumor 
stage. Age at diagnosis was lower for PLCRC participants in all stages, and discrepancies increased by stage  (dage 
from 0.28 in stage I to 0.55 in stage IV). For all disease stages, PLCRC contained relatively more patients with a 
primary tumor in the rectum and fewer patients with a primary tumor in the colon, compared with the Dutch-
ref  (dpr.tumor between 0.14 and 0.25). The proportions of sex and BMI at diagnosis were comparable to the ref. 
population in all stages  (dsex between 0.08 and 0.19,  dbmi between 0.01 and 0.08).
Discussion
Over the past six years, the increased number of PLCRC recruiting centers has resulted in a steep increase in 
participating patients, with excellent consent rates for PROs, blood and tissue biobanking, and participation in 
future research within PLCRC. Although we found an overall shift towards the Dutch-ref for patients enrolled 
between 2017–Aug 2019, regular hospitals remain underrepresented as participating centers to enroll patients 
and PLCRC participants were still younger and more often had stage III disease, as compared to the total Dutch 
CRC population.
Besides common discrepancies such as performance status and number of comorbidities, clinical trial par-
ticipants are notably younger than the real-world population, which for now might hamper the applicability of 
trial results in daily clinical practice. It was recently shown that phase-III RCT patients were on average seven 
years younger than the general CRC  population23. Similarly, patients within PLCRC are younger compared to 
the Dutch-ref, however, this difference only is 4 years (mean age 65 years). Standardized differences for age 
increased by tumor stage, with stage IV patients showing a mean age comparable to phase-III clinical trials in 
Figure 4.  Completion rates of questionnaires until three years after enrollment. Overall completion rates are 
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Baseline characteristics Totala (n = 5722) Stage I (n = 851) Stage II (n = 1079) Stage III (n = 1960) Stage IV (n = 946) Stage  missingd (n = 886)
Demographic and clinical characteristicsb
Year of enrollment (n = 5722)
2013–2016 1088 (19%) 160 (19%) 213 (20%) 462 (24%) 253 (27%) 0 (0%)
2017 1343 (24%) 240 (28%) 326 (33%) 512 (26%) 264 (28%) 1 (< 1%)
2018 2128 (37%) 369 (43%) 421 (39%) 759 (39%) 314 (33%) 265 (30%)
2019 (until August) 1163 (20%) 82 (10%) 119 (11%) 227 (12%) 115 (12%) 620 (70%)
Age at enrollment (n = 5722) 66.3 ± 10.6 67.7 ± 8.9 68.2 ± 10.3 65.7 ± 10.5 63.8 ± 10.9 66.7 ± 11.6
< 55 years 720 (13%) 49 (6%) 95 (9%) 263 (13%) 196 (21%) 117 (13%)
55–64 years 1652 (29%) 240 (28%) 290 (27%) 582 (30%) 286 (30%) 254 (29%)
65–74 years 2040 (36%) 372 (44%) 386 (36%) 708 (36%) 308 (33%) 266 (30%)
75–84 years 1117 (20%) 165 (19%) 249 (23%) 365 (19%) 140 (15%) 198 (22%)
 ≥ 85 years 193 (3%) 25 (3%) 59 (6%) 42 (2%) 16 (2%) 51 (6%)
Days from diagnosis to enrollment 
(n = 5722) 18 (1;131) 14 (0;45) 13 (-2;66) 23 (3;156) 188 (23;670) 4 (-10;20)
< 31 days 3397 (59%) 595 (70%) 719 (67%) 1087 (56%) 269 (28%) 727 (82%)
31–90 days 693 (12%) 109 (13%) 112 (10%) 255 (13%) 106 (11%) 111 (13%)
91–365 days 637 (11%) 61 (7%) 79 (7%) 239 (12%) 211 (22%) 47 (5%)
> 365 days 995 (17%) 86 (10%) 169 (16%) 379 (19%) 360 (38%) 1 (< 1%)
Sex (n = 5722)
Male 3526 (62%) 532 (63%) 685 (64%) 1196 (61%) 583 (62%) 530 (60%)
Female 2196 (38%) 319 (38%) 394 (36%) 764 (39%) 363 (38%) 356 (40%)
Primary tumor location (n = 5722)
Rectum (C19.9, C20.9) 2231 (39%) 321 (38%) 347 (32%) 1023 (52%) 364 (38%) 176 (20%)
Colon (C18.0–18.9) 3491 (61%) 530 (62%) 732 (68%) 937 (48%) 582 (62%) 710 (80%)
Right colon (C18.0–18.4) 1403 (40%) 254 (48%) 410 (56%) 432 (46%) 253 (44%) 54 (8%)
Left colon (C18.5–18.7) 1564 (45%) 270 (51%) 309 (42%) 489 (52%) 315 (54%) 181 (25%)
Colon unspecified (C18.8–18.9) 524 (15%) 6 (1%) 13 (2%) 16 (2%) 14 (2%) 475 (67%)
Location synchronous metastases (n = 5722)
Liver 746 (13%) 746 (79%)
Lung 212 (4%) 212 (22%)
Peritoneal 163 (3%) 163 (17%)
Molecular diagnostics (n = 570–2600, missing 55–90%)
RAS mutation status determined 596 (10%) 9 (1%) 30 (3%) 119 (6%) 438 (46%) 0 (0%)
BRAF mutation status determined 570 (10%) 14 (2%) 48 (4%) 121 (6%) 387 (41%) 0 (0%)
Microsatellite instability (MSI) determined 2600 (45%) 436 (51%) 582 (54%) 1097 (56%) 483 (51%) 2 (< 1%)
BMI at enrollment, kg/m2 (n = 3108, missing 
46%)c 26.3 ± 4.5 27.1 ± 4.6 26.3 ± 4.6 26.1 ± 4.2 25.8 ± 5.0 26.2 ± 4.3
Underweight (< 18.5) 37 (1%) 2 (< 1%) 7 (1%) 11 (1%) 7 (1%) 10 (2%)
Normal weight (18.5–25) 1313 (42%) 170 (37%) 198 (39%) 466 (43%) 261 (48%) 218 (41%)
Overweight (25–30) 1254 (40%) 185 (40%) 214 (43%) 435 (40%) 199 (37%) 221 (42%)
Obese (> 30) 504 (16%) 101 (22%) 83 (17%) 165 (15%) 74 (14%) 81 (15%)
Past 12 months treated for chronic disease, at enrollment (n = 2986, missing 48%)c
Cardiac disease or stroke 313 (11%) 59 (13%) 42 (9%) 114 (11%) 44 (9%) 54 (11%)
Diabetes 290 (10%) 38 (9%) 58 (12%) 117 (11%) 27 (5%) 50 (10%)
Liver disease 184 (6%) 11 (3%) 18 (4%) 35 (3%) 112 (22%) 8 (2%)
Kidney disease 38 (1%) 5 (1%) 6 (1%) 13 (1%) 7 (1%) 7 (1%)
Smoking status at enrollment (n = 3140, missing 45%)c
Current 231 (7%) 23 (5%) 54 (11%) 74 (7%) 46 (8%) 34 (6%)
Former 1840 (59%) 293 (63%) 286 (56%) 646 (59%) 298 (55%) 317 (59%)
Never 1069 (34%) 149 (32%) 168 (33%) 368 (34%) 200 (37%) 184 (34%)
Past month average alcohol consumption at enrollment (n = 3111, missing 46%)c
0 units per day 1167 (38%) 134 (29%) 165 (33%) 403 (37%) 259 (48%) 206 (39%)
0–1 units per day 1223 (39%) 195 (42%) 211 (42%) 400 (37%) 196 (36%) 221 (42%)
1–2 units per day 464 (15%) 82 (18%) 75 (15%) 182 (17%) 58 (11%) 67 (13%)
> 2 units per day 257 (8%) 50 (11%) 52 (10%) 94 (9%) 26 (5%) 35 (7%)
Living situation at enrollment (n = 3144, missing 45%)c
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metastatic CRC 24. This emphasizes the need to focus on the enrollment of (stage IV) patients that are diagnosed at 
older age. Although important factors such as comorbidities and performance status are currently unknown, we 
believe that PLCRC has the potential to serve as a research platform that fulfills the current demand for RWD as 
advocated for by regulators and research community. The additional advantage of PLCRC is the large collection 
of biospecimen, which is intertwined with routine clinical care, and longitudinal PROs from diagnosis onwards. 
Moreover, the incorporation of PROs that describe the impact of treatment on quality of life, daily activities and 
symptoms is increasingly recognized as an essential component of real-world evidence and has the potential to 
improve cancer care, shared decision making, and clinical  outcomes25–27.
Dutch CRC guidelines recommend, in line with the European guidelines, to determine both mismatch repair 
status in stage II-IV tumors, and RAS and BRAF mutation status in tumor of patients with metastatic CRC prior 
to the start of systemic  treatment28–30. Although our percentages may be an underestimation as mutation status 
could become available during NCR updates after the initial data registration, the amount of missing data on 
molecular diagnostics is noteworthy. A limitation that is currently inevitable within PLCRC is that complete-
ness of the NCR depends on daily clinical practices. In contrast to the above mentioned national guidelines, 
molecular markers are not routinely measured in all patients in the clinic. This means that currently, PLCRC 
is missing opportunities to optimally use tumor mutation status for research purposes. Efforts are ongoing to 
perform retrospective molecular profiling within PLCRC to supplement existing molecular pathology data with 
the aim to be able to tailor treatment options to the individual patient in the future. Next to the identification of 
predictors for treatment response and clinical outcomes, this will also contribute to the development of a unique 
cohort that could provide “external” controls for future single arm clinical trials in uncommon CRC subtypes 
with high unmet medical  need31,32.
Given the large variety of available data, PLCRC will allow for comprehensive analyses on CRC. However, 
future improvements are required to optimize two fundamental elements of RWD sources: completeness of cases 
and completeness of clinical data. Based on our experience, over 90% of patients provide informed consent once 
the study aim is explained. Enhanced integration of research into daily clinical practice and the development of 
local infrastructures that lead to increased willingness and availability of personnel to inform the patient about 
PLCRC, especially in regular hospitals, are crucial to further improve the completeness of cases and create a true 
RWD cohort. Second, completeness of clinical data mainly depends on how well clinicians document clinical 
data in EHRs. Regardless of the list of items to be collected in the NCR, unmeasured or undocumented data will 
never become available to the research community. Moreover, EHR data are often unstructured and inconsistent 
due to large variation between clinicians and differences in EHR software systems. Bertagnolli and  colleagues33 
recently stated that the use of data obtained during routine clinical care as “real-world” data to fuel a learning 
healthcare system is currently still in its infancy. Prior to utilizing EHRs to facilitate a learning health system, 
EHRs must contain readily exchangeable and clinically meaningful structured data elements of adequate quality 
to draw valid  inferences33. Therefore, we emphasize that nationwide harmonization and standardization of clini-
cal data entries in EHRs and subsequent implementation of electronic data-capture systems to enable real-time 
data transfer from EHRs to the NCR, will significantly enhance the completeness and quality of clinical data.
Future focus should be given to reaching and enrolling older patients and to enhance involvement of the 
gastroenterology departments to enroll patients with early stage tumors. Moreover, especially stage IV patients 
should be enrolled closer to diagnosis to standardize time points for PROs and avoid potential survivor bias. 
This can be achieved by an optimal research-focused infrastructure and implementation of research-specific 
consultations for all cancer patients shortly after diagnosis. During this consultation, the patient is informed 
about the specific components of PLCRC (Box 1), as well as on the main aim to optimally evaluate treatments, 
accelerate innovation, and learn from each individual patient. Such an infrastructure will also contribute to 
enrolling patients with the least hospital visits, e.g. patients with a polypectomy only, or extensively metastasized 
disease with rapid progression and best supportive care only. Besides the aforementioned suggestions, we need 
to create a societal change with respect to clinical research. All stakeholders should be aware that, in order to 
improve oncology practice, research needs to become an integrated part of clinical care and that contributions 
to clinical research are self-evident. Lastly, PLCRC is a platform to centralize national CRC research to maximize 
Table 1.  Baseline descriptive demographic and clinical characteristics at PLCRC enrollment, stratified by 
tumor stage. Descriptives are presented as count (%), mean (± SD), or median (IQR). a N = 22 patients with 
permanently unknown tumor stage are not included in the analysis. b In case of missing data, the descriptive 
statistics of complete cases are presented. c Self-reported. d PLCRC is a dynamic cohort with continuous new 
enrollment and data-linkage. The high percentage of missing data, is due to the time-lag between enrollment 
and data linkage from the NCR to PLCRC, which is continuously updated.
Baseline characteristics Totala (n = 5722) Stage I (n = 851) Stage II (n = 1079) Stage III (n = 1960) Stage IV (n = 946) Stage  missingd (n = 886)
Living with partner, without children 1965 (63%) 324 (70%) 322 (63%) 679 (62%) 313 (57%) 327 (61%)
Living with partner and children 537 (17%) 51 (11%) 82 (16%) 189 (17%) 120 (22%) 95 (18%)
Living alone with children 69 (2%) 8 (2%) 12 (2%) 26 (2%) 12 (2%) 11 (2%)
Other 43 (1%) 8 (2%) 5 (1%) 13 (1%) 11 (2%) 6 (1%)
Educational level (n = 3108, missing 46%)c
≤ High school 1206 (39%) 201 (44%) 194 (39%) 401 (37%) 192 (36%) 218 (41%)
Trade / college / other non-university 1548 (50%) 212 (46%) 256 (51%) 539 (50%) 278 (51%) 263 (49%)
University 354 (11%) 45 (10%) 53 (10%) 135 (13%) 70 (13%) 51 (10%)
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:3923  | https://doi.org/10.1038/s41598-020-79890-y
www.nature.com/scientificreports/
its potential and minimize patient burden. Access to cohort resources for collaborative research projects may be 
requested through the Scientific Committee [https ://plcrc .nl/for-inter natio nal-visit ors] that reviews all research 
projects for approval.
To conclude, PLCRC is establishing a unique and steeply growing national RWD cohort that allows for a wide 
range of research. Data from the general patient population enables a learning healthcare system that provides 
insight into the care and outcomes of patients that are usually underrepresented in RCTs, e.g. the very young and 
older patients and the ones with multiple comorbidities. Comprehensive analyses within PLCRC are facilitated 
by the extensive amount of clinical data covering the complete treatment trajectory and additional patient-
reported outcomes. Further improvements in recruitment methodologies and multidisciplinary enrollment of 
Table 2.  Characteristics of PLCRC participants at diagnosis (2013-Aug’19), compared with the general 
Dutch CRC population (2013–’17), and stratified by time-period (2013–’16, and 2017–Aug’19). a Standardized 
differences (d) are differences in means or proportions divided by standard error; d > 0.20 indicate a large 
difference, d 0.10–0.20 indicate a small difference, and d < 0.10 indicate a negligible  difference17,18. b BMI 
at diagnosis for PLCRC only available when participants were enrolled at diagnosis and provided PROs 
(n = 1244); the NCR only collected height and weight in 2015, thus the reference values for BMI originate only 




















Aug’19 (n = 3671)
Standardized 
difference (d)a
Age at diagnosis 69.3 ± 10.8 64.9 ± 10.5 0.41 64.6 ± 10.2 0.45 65.0 ± 10.6 0.40
< 55 years 6476 (9%) 733 (15%) 170 (16%) 563 (15%)
55–64 years 15,248 (21%) 1470 (31%) 350 (32%) 1120 (31%)
65–74 years 26,602 (37%) 1722 (36%) 395 (36%) 1327 (36%)
75–84 years 19,482 (27%) 729 (15%) 153 (14%) 576 (16%)
 ≥ 85 years 4877 (7%) 105 (2%) 20 (2%) 85 (2%)
Sex 0.11 0.17 0.09
Male 41,115 (57%) 2949 (62%) 704 (65%) 2245 (61%)
Female 31,570 (43%) 1810 (38%) 384 (35%) 1426 (39%)
BMI at diagnosisb 
(kg/m2) 26.6 ± 4.6 26.6 ± 4.8 0.01 25.9 ± 4.0 0.16 26.7 ± 4.9 0.03
Underweight (< 18.5) 228 (2%) 10 (1%) 1 (1%) 9 (1%)
Normal weight 
(18.5–24.9) 5252 (38%) 502 (40%) 78 (47%) 424 (39%)
Overweight 
(25–29.9) 5625 (41%) 503 (40%) 61 (37%) 442 (41%)
Obese (≥ 30) 2691 (20%) 229 (18%) 26 (16%) 203 (19%)
Primary tumor 
locationc 0.24 0.53 0.16
Rectum (C19.9, 
C20.9) 22,426 (31%) 2025 (43%) 610 (56%) 1415 (39%)
Colon (C18.0–18.7) 50,259 (69%) 2734 (57%) 478 (44%) 2256 (61%)
Right colon 
(C18.0–18.4) 24,244 (48%) 1330 (49%) 200 (42%) 1130 (50%)
Left colon 
(C18.5–18.7) 24,634 (49%) 1359 (50%) 269 (56%) 1090 (48%)
Colon unspecified 
(C18.8–18.9) 1381 (3%) 45 (2%) 9 (2%) 36 (2%)
TNM 0.24 0.33 0.22
Stage I 17,686 (24%) 849 (18%) 160 (15%) 689 (19%)
Stage II 17,951 (25%) 1063 (22%) 213 (20%) 850 (23%)
Stage III 21,707 (30%) 1929 (41%) 462 (42%) 1467 (40%)
Stage IV 15,341 (21%) 918 (19%) 253 (23%) 665 (18%)
Location synchronous metastases
Liver 11,218 (15%) 722 (15%) 0.01 202 (19%) 0.08 520 (14%) 0.04
Lung 3954 (5%) 209 (4%) 0.05 58 (5%) 0.00 151 (4%) 0.06
Peritoneal 3673 (5%) 162 (3%) 0.08 42 (4%) 0.06 120 (3%) 0.09
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patients will contribute to the aim of enrolling all newly diagnosed CRC patients in the Netherlands. This will 
continue to enhance PLCRC’s representation of the real-world and its ability to improve both scientific research 
and daily clinical practice.
Data availability
Access to cohort resources for collaborative research projects may be requested through the Scientific Committee 
[https ://plcrc .nl/for-inter natio nal-visit ors] that reviews all research projects for approval.
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